1105634-93-2Relevant articles and documents
Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation
Fioravanti, Rossella,Romanelli, Annalisa,Mautone, Nicola,Di Bello, Elisabetta,Rovere, Annarita,Corinti, Davide,Zwergel, Clemens,Valente, Sergio,Rotili, Dante,Botrugno, Oronza A.,Dessanti, Paola,Vultaggio, Stefania,Vianello, Paola,Cappa, Anna,Binda, Claudia,Mattevi, Andrea,Minucci, Saverio,Mercurio, Ciro,Varasi, Mario,Mai, Antonello
, p. 643 - 658 (2020)
Abstract: LSD1 is a lysine demethylase highly involved in initiation and development of cancer. To design highly effective covalent inhibitors, a strategy is to fill its large catalytic cleft by designing tranylcypromine (TCP) analogs decorated with long,
NOVEL THERAPEUTIC COMPOUNDS
-
Page/Page column 80-81, (2009/03/07)
Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.